Jean-Simon Diallo

List of Publications by Year in Descending Order

69 papers	2,782 citations	28 h-index	52 g-index
73 ext. papers	3,278 ext. citations	9.9 avg, IF	4.66 L-index

#	Paper	IF	Citations
69	Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.. *Nature Communications*, **2022**, 13, 1898	17.4	0
68	Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy.. *Molecular Therapy - Oncolytics*, **2022**, 25, 146-159	6.4	1
67	Single-dose replicating poxvirus vector-basedRBD vaccine drives robust humoral and T□cellimmune response against SARS-CoV-2 infection. *Molecular Therapy*, **2021**,	11.7	2
66	Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern. *ACS Infectious Diseases*, **2021**, 7, 3034-3051	5.5	2
65	Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta-analysis. *Hematological Oncology*, **2021**, 39, 448-464	1.3	0
64	SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. *Biosensors and Bioelectronics*, **2021**, 180, 113122	11.8	9
63	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2□S for viral entry. *Molecular Therapy*, **2021**, 29, 1984-2000	11.7	13
62	Actin-Related Protein 6 (Arp6) Influences Double-Strand Break Repair in Yeast. *Applied Microbiology* , **2021**, 1, 225-238		
61	Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	11
60	Personalized oncology and BRAF melanoma: model development, drug discovery, and clinical correlation. *Journal of Cancer Research and Clinical Oncology*, **2021**, 147, 1365-1378	4.9	0
59	Immunotherapy for sarcomas: new frontiers and unveiled opportunities **2021**, 9,		11
58	Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. *Molecular Therapy - Oncolytics*, **2021**, 20, 306-324	6.4	5
57	The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy. *Communications Biology*, **2020**, 3, 254	6.7	5
56	Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. *BMJ Open*, **2020**, 10, e034714	3	5
55	A Systematic Review of Evidence Supporting the Use of Autologous Cell Vaccines in the Treatment of Hematological Malignancies. *Blood*, **2020**, 136, 16-16	2.2	
54	Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy. *Molecular Therapy - Oncolytics*, **2020**, 19, 240-252	6.4	
53	Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization. *Membranes*, **2020**, 10,	3.8	10

52	SnapShot: Cancer Immunotherapy with Oncolytic Viruses. *Cell*, **2019**, 176, 1240-1240.e1	56.2	29
51	Enhancement of oncolytic virotherapy by vanadium(V) dipicolinates. *BioMetals*, **2019**, 32, 545-561	3.4	11
50	Viral Vectors for Treatment of Human Disease: Therapeutic and Manufacturing Challenges **2019**, 213-246		1
49	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. *Molecular Therapy - Oncolytics*, **2019**, 14, 179-187	6.4	11
48	Development of a novel screening platform for the identification of small molecule inhibitors of human adenovirus. *Virology*, **2019**, 538, 24-34	3.6	8
47	Dimethyl fumarate potentiates oncolytic virotherapy through NF-B inhibition. *Science Translational Medicine*, **2018**, 10,	17.5	28
46	Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. *Science Translational Medicine*, **2018**, 10,	17.5	164
45	Does Treatment Order Matter? Investigating the Ability of Bacteriophage to Augment Antibiotic Activity against Biofilms. *Frontiers in Microbiology*, **2018**, 9, 127	5.7	79
44	Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis. *PLoS Pathogens*, **2018**, 14, e1007264	7.6	11
43	Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds. *Molecular Therapy*, **2018**, 26, 56-69	11.7	55
42	Development and applications of oncolytic Maraba virus vaccines. *Oncolytic Virotherapy*, **2018**, 7, 117-128		24
41	Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy. *ACS Infectious Diseases*, **2018**, 4, 1448-1467	5.5	23
40	Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma. *International Journal of Cancer*, **2017**, 141, 1257-1264	7.5	23
39	Customized Viral Immunotherapy for HPV-Associated Cancer. *Cancer Immunology Research*, **2017**, 5, 847-859	12.5	29
38	Oncolytic vesicular stomatitis virus expressing interferon- has enhanced therapeutic activity. *Molecular Therapy - Oncolytics*, **2016**, 3, 16001	6.4	46
37	First-in-class small molecule potentiators of cancer virotherapy. *Scientific Reports*, **2016**, 6, 26786	4.9	21
36	Single-particle characterization of oncolytic vaccinia virus by flow virometry. *Vaccine*, **2016**, 34, 5082-5089	4.1	19
35	Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. *Breast Cancer Research*, **2016**, 18, 83	8.3	53

34	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. *Cancer Cell*, **2015**, 28, 210-24	24.3	62
33	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. *Nature Communications*, **2015**, 6, 6410	17.4	36
32	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. *Nature Medicine*, **2015**, 21, 530-6	50.5	93
31	Oncolytic Viruses: Exploiting Cancer'ƃ Deal with the Devil. *Trends in Cancer*, **2015**, 1, 266-277	12.5	54
30	High-throughput titration of luciferase-expressing recombinant viruses. *Journal of Visualized Experiments*, **2014**, 51890	1.6	6
29	From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. *PLoS Pathogens*, **2014**, 10, e1003836	7.6	48
28	Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells. *PLoS ONE*, **2014**, 9, e102365	3.7	14
27	Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses. *Frontiers in Oncology*, **2014**, 4, 191	5.3	22
26	Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. *Journal of Virology*, **2013**, 87, 2363-6	6.6	15
25	Model-based rational design of an oncolytic virus with improved therapeutic potential. *Nature Communications*, **2013**, 4, 1974	17.4	35
24	HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. *Molecular Therapy*, **2013**, 21, 887-94	11.7	85
23	Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. *Clinical Cancer Research*, **2013**, 19, 3832-43	12.9	23
22	Exploiting tumor epigenetics to improve oncolytic virotherapy. *Frontiers in Genetics*, **2013**, 4, 184	4.5	15
21	Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. *Molecular Therapy*, **2012**, 20, 1791-9	11.7	56
20	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. *Molecular Therapy*, **2012**, 20, 749-58	11.7	177
19	Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. *Methods in Molecular Biology*, **2012**, 797, 127-40	1.4	27
18	Influence of pH on the Cytotoxic Activity of Inositol Hexakisphosphate (IP6) in Prostate Cancer. *Frontiers in Oncology*, **2011**, 1, 40	5.3	1
17	Ex vivo infection of live tissue with oncolytic viruses. *Journal of Visualized Experiments*, **2011**,	1.6	13

16	Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. *Nature*, **2011**, 477, 99-102	50.4	392
15	A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. *Molecular Therapy*, **2011**, 19, 1913-22	11.7	117
14	A novel method of cell embedding for tissue microarrays. *Histopathology*, **2010**, 57, 323-9	7.3	5
13	A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. *Molecular Therapy*, **2010**, 18, 1123-9	11.7	67
12	Synergistic interaction between oncolytic viruses augments tumor killing. *Molecular Therapy*, **2010**, 18, 888-95	11.7	97
11	Intelligent design: combination therapy with oncolytic viruses. *Molecular Therapy*, **2010**, 18, 251-63	11.7	150
10	Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. *PLoS ONE*, **2010**, 5, e14462	3.7	54
9	Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. *Prostate*, **2009**, 69, 706-18	4.2	30
8	Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. *BJU International*, **2008**, 101, 1302-9	5.6	19
7	Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 14981-6	11.5	146
6	Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. *BJU International*, **2007**, 100, 303-9	5.6	28
5	NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. *Cellular Signalling*, **2007**, 19, 1093-100	4.9	24
4	Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer. *Molecular Cancer Research*, **2007**, 5, 87-94	6.6	16
3	NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. *Clinical Cancer Research*, **2007**, 13, 7044-52	12.9	30
2	Expression and nuclear localization of ErbB3 in prostate cancer. *Clinical Cancer Research*, **2006**, 12, 2730-7	12.9	99
1	An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. *Prostate*, **2006**, 66, 1245-56	4.2	15